Welcome to our dedicated page for EFFECTOR THERAPUTCS news (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on EFFECTOR THERAPUTCS stock.
eFFECTOR Therapeutics, Inc., headquartered in San Diego, is a cutting-edge biotechnology company that focuses on developing a novel class of oncology drugs known as selective translation regulator inhibitors (STRIs). The company's mission is to advance cancer treatment by targeting key molecular mechanisms that drive the disease.
eFFECTOR's flagship product, zotatifin, is currently under Phase 1/2 clinical trials for ER+/HER2- metastatic breast cancer. Recently, zotatifin received Fast Track designation from the U.S. FDA in combination with fulvestrant and abemaciclib, underscoring its potential in treating advanced or metastatic breast cancer. In these trials, zotatifin showed promising results with a 26% partial response rate in heavily pretreated patients.
Another key product in eFFECTOR's pipeline is tomivosertib, an MNK inhibitor being evaluated in a Phase 2b trial for metastatic non-small cell lung cancer (NSCLC). The company's research extends to other biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.
eFFECTOR is also collaborating globally with Pfizer to develop inhibitors targeting eIF4E, further enhancing its research capabilities and clinical development. This partnership aims to streamline the translation of groundbreaking findings into viable treatments for cancer patients.
Financially, eFFECTOR continues to strengthen its position through strategic offerings, raising approximately $15 million in recent direct offerings. This capital helps advance their research projects and maintain a robust developmental pipeline.
Additionally, eFFECTOR announced a reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024. This move is intended to better position the company within the stock market, ensuring long-term growth and stability.
Stay updated with eFFECTOR's latest developments as they continue to innovate in the field of oncology, pushing the boundaries of cancer treatment.
eFFECTOR Therapeutics (NASDAQ: EFTR) reported its fourth quarter and full year 2022 financial results on March 8, 2023. The company’s revenue rose to $3.6 million for 2022, up from $1.4 million in 2021, primarily from grant revenue. However, net losses increased to $22.7 million or $0.55 per share, compared to a net income of $15.8 million in 2021. eFFECTOR is advancing its clinical assets, zotatifin and tomivosertib, toward late-stage development. Enrollment in the expanded zotatifin cohort has been completed, and topline data is expected in the first half of 2023, with cash runway extended into Q1 2024.
eFFECTOR Therapeutics announced positive top-line results from its Phase 1b clinical trial of zotatifin for treating COVID-19, presented at the 30th Conference on Retroviruses and Opportunistic Infections. The trial indicated favorable safety results, with zotatifin showing a quicker time to undetectable virus levels in saliva compared to placebo—3 days versus 7 days, respectively. Zotatifin was well tolerated and achieved target drug levels via a single subcutaneous injection. Preclinical data further demonstrated its effectiveness against various RNA viruses. The company believes these findings support continued development of zotatifin for COVID-19 and potential other RNA virus treatments.
eFFECTOR Therapeutics (NASDAQ: EFTR) is set to present and host meetings at the 2023 BIO CEO & Investor Conference in New York from February 6-9, 2023. CEO Steve Worland will discuss the clinical development pipeline and corporate strategy on February 6 at 2:15 PM ET at the New York Marriott Marquis. The company specializes in selective translation regulator inhibitors (STRIs) aimed at treating cancer, focusing on their lead drug tomivosertib, which is in a Phase 2b trial for non-small cell lung cancer. eFFECTOR also collaborates with Pfizer on eIF4E inhibitors and investigates zotatifin for COVID-19 treatment.
eFFECTOR Therapeutics (NASDAQ: EFTR) reported progress in ongoing clinical trials for zotatifin and tomivosertib, targeting estrogen receptor-positive breast cancer and KRAS non-small cell lung cancer. Zotatifin showed a 29% objective response rate in patients receiving a combination therapy with good tolerability. The company resumed dose escalation for zotatifin, anticipating more data in 2023. For tomivosertib, challenges in clinical trial enrollment persist, leading to a suspension of one cohort while focusing on a key PD-L1 cohort. Top-line data for both drugs is expected later in 2023.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced key executive appointments and clinical trial updates in its latest press release. Douglas Warner, M.D. is appointed as CMO, and Mayank Gandhi, M.D. as CBO. The company expanded its Phase 1b trial cohort for ER+ breast cancer from 7 to 18 patients and initiated dosing for a second cohort treating COVID-19. Financially, EFTR reported a net loss of $9.6 million for Q3 2022, down from a net income of $8.9 million in the same period last year. Cash reserves decreased to $33 million, projected to fund ongoing clinical trials into 2023.
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced participation in two upcoming investor conferences. The management team will host a Fireside Chat at the Credit Suisse 31st Annual Healthcare Conference on November 8th at 2 PM PT, followed by another at the Stifel 2022 Healthcare Conference on November 15th at 9:10 AM ET. Live webcasts of both events will be available on the company's Investors page, with replays accessible for 30 days post-event. eFFECTOR develops selective translation regulator inhibitors (STRIs) targeting cancer treatment.
eFFECTOR Therapeutics (NASDAQ: EFTR) has completed enrollment for the second cohort of its Phase 1b clinical trial of zotatifin, aimed at treating COVID-19 in non-hospitalized adults. The company is set to initiate enrollment for the third cohort by late 2022 and expects to release topline data from all cohorts in the first half of 2023. Zotatifin acts as a host-directed antiviral, potentially offering a therapeutic advantage over traditional virus-targeting agents. The trial is conducted in collaboration with UCSF and is supported by a $5 million contract from DARPA.
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) has appointed Mayank J. Gandhi, M.D., as chief business officer to spearhead corporate growth and business development. Dr. Gandhi brings over 15 years of biopharmaceutical experience, previously working with Jiya Acquisition Group and Genentech. His focus will be maximizing the value of tomivosertib and zotatifin, which have shown promising clinical data. This leadership change comes at a critical time as both drug candidates progress in clinical trials, potentially enhancing eFFECTOR's position in oncology.
eFFECTOR Therapeutics (NASDAQ: EFTR) will participate in a panel discussion at the Cantor Oncology, Hematology, HemeOnc Conference on September 28, 2022, from 10:40 AM ET to 11:20 AM ET. The panel is titled “Building Combinations: What are the Novel Ideas?” and will feature Steve Worland, Ph.D., President and CEO. eFFECTOR is focused on developing selective translation regulator inhibitors (STRIs) for cancer treatment, with ongoing trials for lead candidate tomivosertib and zotatifin. For more details, visit: Cantor Conference.
eFFECTOR Therapeutics (NASDAQ: EFTR) announced the dosing of the first patient in the second cohort of its Phase 1b clinical trial for zotatifin, aimed at treating COVID-19. This trial follows a positive recommendation from an independent data safety monitoring board after reviewing safety data from the first cohort. The trial, in partnership with the Quantitative Biosciences Institute, evaluates a single dose of zotatifin, which showed equivalent drug levels via subcutaneous delivery compared to IV. The investigational drug targets eIF4A to inhibit viral replication and may offer a novel treatment option.
FAQ
What is the current stock price of EFFECTOR THERAPUTCS (EFTR)?
What is the market cap of EFFECTOR THERAPUTCS (EFTR)?
What is eFFECTOR Therapeutics' primary focus?
What recent achievement did eFFECTOR announce?
What products are in eFFECTOR's pipeline?
How is eFFECTOR collaborating with other companies?
What are the financial highlights of eFFECTOR?
What is the significance of the recent reverse stock split?
What types of cancer are eFFECTOR's products targeting?
What is the potential benefit of zotatifin's Fast Track designation?
How is eFFECTOR funded for its developments?
What are the recent clinical trial results for zotatifin?
